June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retinal Oxygenation During Intravitreal Treatment for Central Retinal Vein Occlusion
Author Affiliations & Notes
  • Sindri Traustason
    Dept of Ophthalmology,Glostrup Univ Hosp, Copenhagen University, Glostrup, Denmark
  • Morten de La Cour
    Dept of Ophthalmology,Glostrup Univ Hosp, Copenhagen University, Glostrup, Denmark
  • Michael Larsen
    Dept of Ophthalmology,Glostrup Univ Hosp, Copenhagen University, Glostrup, Denmark
  • Footnotes
    Commercial Relationships Sindri Traustason, Novartis (F), Oxymap (R); Morten de La Cour, Alcon (C), Novartis (C); Michael Larsen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4646. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sindri Traustason, Morten de La Cour, Michael Larsen; Retinal Oxygenation During Intravitreal Treatment for Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4646. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Intravitreal ranibizumab has in recent years become standard of care treatment for macular edema in central retinal vein occlusion. While the treatment generally reduces macular edema and improves visual acuity, cases of increased retinal ischemia have been reported. The purpose of this study was to investigate the effect of intravitreal anti-VEGF on retinal oxygenation in patients with central retinal vein occlusion.

 
Methods
 

Patients with central retinal vein occlusion in one eye were included in a prospective single-group observational study. Included patients received treatment according to standard clinical procedure and were followed over a period of six month. All patients received three initial monthly injections of intravitreal ranibizumab (Lucentis, Novartis), followed by a three month follow-up period, during which injections were given as needed. At each visit, patients underwent examinations which included best corrected visual acuity, central macular thickness with SD-OCT and retinal oximetry.

 
Results
 

At baseline, retinal venous oxygen saturation was reduced in the affected eye, compared to fellow eye (35 ± 14% and to 57 ± 9%, respectively, mean ± SD, p = 3.1 x 10-5, paired t-test). Retinal venous oxygen saturation and BCVA increased and macular thickness decreases during ranibizumab treatment. No significant changes were found in retinal arterial saturation (Fig. 1).

 
Conclusions
 

Our results indicate that retinal venous saturation is increased during treatment with intravitreal ranibizumab and do not point towards increased retinal ischemia.

 
 
Changes in retinal oximetry, best corrected visual acuity (BCVA) on the ETDRS scale and central retinal thickness (OCT) from baseline to month 4 and 7. P-values indicate results from one sample t-tests (μ=0).
 
Changes in retinal oximetry, best corrected visual acuity (BCVA) on the ETDRS scale and central retinal thickness (OCT) from baseline to month 4 and 7. P-values indicate results from one sample t-tests (μ=0).
 
Keywords: 635 oxygen • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×